Search - tctmd.com

Displaying 1 - 20 of 37

Sort: Relevancy | Date

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

News Conference News TCT 2025

ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR

October 27, 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

News Conference News TCT 2025

Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC

Yael L. Maxwell

October 27, 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

News Conference News TCT 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

Michael O'Riordan

October 27, 2025

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

October 30, 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

News Conference News TCT 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

Yael L. Maxwell

October 29, 2024

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

ALIGN-AR: Positive Results for Trilogy Valve in Aortic Regurgitation

News Conference News TCT 2023

ALIGN-AR: Positive Results for Trilogy Valve in Aortic Regurgitation

October 26, 2023

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

News Conference News TCT 2022

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

September 19, 2022

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

News Conference News TCT 2021

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

Yael L. Maxwell

November 06, 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

November 05, 2021

Acurate Neo Still Falls Short of Sapien 3 in SCOPE 1-Year Follow-up

News Conference News TCT 2020

Acurate Neo Still Falls Short of Sapien 3 in SCOPE 1-Year Follow-up

Michael O'Riordan

October 23, 2020

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

News Conference News TCT 2020

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

Michael O'Riordan

October 15, 2020

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

News Conference News TCT 2019

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

September 29, 2019

SCOPE I: Acurate Neo Comes Up Short for Severe Aortic Stenosis

News Conference News TCT 2019

SCOPE I: Acurate Neo Comes Up Short for Severe Aortic Stenosis

Marcus A. Banks

September 27, 2019

TCT Live Blog Day 2

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Two: Transcatheter Valves, New and Old

September 27, 2019

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

News Conference News TCT 2019

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

Michael O'Riordan

September 25, 2019

PORTICO I: Low 1-Year Mortality With Repositionable TAVR Valve in OUS Experience

News Conference News TCT 2018

PORTICO I: Low 1-Year Mortality With Repositionable TAVR Valve in OUS Experience

September 27, 2018

NEOPRO: Two Next-Gen TAVR Valves Show Promise at 30 Days

News Conference News TCT 2018

NEOPRO: Two Next-Gen TAVR Valves Show Promise at 30 Days

Yael L. Maxwell

September 25, 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

News Conference News TCT 2016

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

November 01, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.